Astellas: Good Results In Enzalutamide Phase III Trials For Prostate Cancer
This article was originally published in PharmAsia News
Executive Summary
Astellas achieved good results in its global Phase III trials with oral androgen receptor inhibitor enzalutamide in the treatment of metastatic prostate cancer patients who have not undergone chemotherapy, the company announced Oct. 22.